Market Cap: $218.5B
AI
Amgen Inc.
AMGN
NASDAQ (NASDAQ Global Select)USD
Market Cap: $218.5B
Amgen (Ticker: AMGN) announces pivotal results from their VESALIUS-CV Phase 3 clinical trial for Repatha, focusing on high-risk diabetic patients and exhibiting a significant reduction in major cardio…
Amgen (Ticker: AMGN) recently showcases groundbreaking results from the Phase 3 VESALIUS-CV subgroup study, shedding light on the benefits of Repatha® for patients grappling with high-risk diabetes. P…
Amgen (Ticker: AMGN) focuses on innovations in cardiometabolic care with recent advancements highlighting its commitment to improving patient outcomes. At the American Diabetes Association's 86th Scie…
Amgen (Ticker: AMGN), a leading biotechnology firm, recently achieves a significant milestone by securing marketing authorization from the European Commission for its drug IMDYLLTRA® (tarlatamab), des…
Amgen Inc (Ticker: AMGN) announces a substantial manufacturing investment strategy focusing on enhancing its biologics production capabilities. In May 2026, Amgen confirms its commitment of $300 milli…
Tavneos' Role in Transforming ANCA-Associated Vasculitis Treatment Amgen navigates a promising path with its innovative therapy Tavneos, specifically approved to treat adults with severe active ANCA-a…
Repatha® Demonstrates Significant Cardiovascular Benefits for High-Risk Diabetes Patients Amgen's recent announcement regarding Repatha® (evolocumab), a groundbreaking PCSK9 inhibitor, marks a signifi…
Amgen Faces Rising Pressure for Affordable Drug Solutions Amidst Industrywide Challenges Amgen, as a leading player in the biotechnology sector, stands at a critical juncture as discussions about pres…
Transforming Drug Affordability: The Emergence of TrumpRx As the pharmaceutical industry grapples with a crisis of affordability, significant innovations are emerging aimed at reducing the financial b…
Amgen Sets to Revolutionize Pharmaceutical Accessibility with Expanded Discount Offerings Amgen announces a significant strategic expansion of its prescription medication offerings, increasing the num…
AMGEN Expands Prescription Offerings to Enhance Healthcare Accessibility Amgen is set to significantly expand its prescription medication offerings, increasing the number of discounted options availab…
Amgen Partners with TrumpRx Initiative to Lower Drug Prices In a decisive move under the TrumpRx initiative, Amgen takes a significant step to lower prescription drug costs, aligning with government g…
Amgen's Role in the TrumpRx Initiative: A Shift Towards Affordable Healthcare Amgen, a leading player in the biopharmaceutical sector, positions itself at the forefront of the TrumpRx initiative, whic…
Amgen's Diverse Analyst Coverage Reflects Complexity in Biotech Landscape Amgen, a leading biotechnology firm, experiences a significant level of scrutiny from financial analysts, with 15 experts weig…
Innovative Adaptations in Biotech: Amgen’s Role in the AI Era In recent discussions surrounding notable biotech stocks, Amgen (NASDAQ: AMGN) finds itself at a critical juncture as the industry increas…
Amgen's Role in the Biotech Revolution: Embracing AI Innovation In the dynamic landscape of biotechnology, Amgen stands out not only for its innovative therapies but also for its ability to adapt to e…
Amgen Gears Up for the Leerink Partners Global Healthcare Conference Amgen, a prominent player in the biotechnology realm, prepares to showcase its latest advancements at the forthcoming Leerink Partn…
Innovation at the Core: Amgen's Continued Commitment to Biotech Leadership In a landscape defined by rapid advancements in biotechnology, Amgen stands as a cornerstone of innovation, continuously resh…
Amgen's Insider Transaction Sparks Investor Inquiry Amgen, a leader in the biopharmaceutical sector, finds itself in the spotlight following a recent insider transaction involving Esteban Santos, the…
### Insider Sale Raises Questions About Strategic Direction at Amgen Amgen's recent insider sale by Executive Vice President Esteban Santos, who offloaded 13,182 shares for approximately $2.7 million,…
Insightful Insider Sale Signals Strategic Direction at Amgen In a significant development for Amgen, Esteban Santos, the Executive Vice President, conducts a noteworthy insider sale of 13,182 shares,…
Amgen Showcases Commitment to Innovation and Access at Upcoming Health Care Conference Amgen, a stalwart in the biotechnology sector with over 45 years of expertise, prepares to present at the 46th An…
Amgen Showcases Leadership in Biotechnology with Upcoming Conference Presentation Amgen, a prominent player in the biotechnology arena, prepares to take the stage at the 46th Annual TD Cowen Health Ca…
Amgen to Present at Upcoming Health Care Conference, Highlighting Commitment to Biotechnology Innovation Amgen, a prominent biotechnology firm firmly rooted in Thousand Oaks, California, is set to pre…
Amgen positions for a GLP‑1 surge as obesity care shifts Amgen is preparing to compete in a rapidly changing obesity-treatment market as GLP‑1 and related modalities reshape care away from traditional…
Amgen readies strategy as GLP-1 obesity market intensifies Amgen is confronting a rapidly intensifying GLP-1-driven obesity market as incumbents and new entrants jockey for share in an expanding treat…
EU authorisation expands Amgen’s neuromuscular portfolio Amgen wins European Commission approval for UPLIZNA (inebilizumab) as an add‑on to standard therapy for adults with generalized myasthenia grav…
Amgen wins EU approval for first CD19 therapy in myasthenia gravis First-in-class CD19 option offers biannual dosing and steroid-sparing promise Amgen announces that the European Commission approves U…
White House drug plan spotlights major manufacturers Amgen's role in TrumpRx direct-to-consumer discount program The White House is unveiling "TrumpRx" as a new direct-to-consumer drug purchasing init…
Market Crosswinds Reinforce Defensive Appeal of Health Care Amgen’s fourth-quarter performance highlights growing investor interest in established biopharmaceuticals as technology names face AI-driven…
Amgen’s fourth-quarter beat points to resilient commercial performance Amgen reports adjusted fourth-quarter earnings of $5.29 per share on $9.87 billion in revenue, both comfortably above LSEG estima…
Amgen’s quarterly outperformance highlights healthcare resilience Amgen reports adjusted fourth-quarter earnings of $5.29 per share on $9.87 billion in revenue, handily topping LSEG estimates of $4.73…
Amgen's Role in the Evolving Pharmaceutical Landscape Amgen, a leader in biotechnology, stands at the intersection of innovation and patient care as the pharmaceutical industry undergoes significant t…
Title: AI-Driven Innovations in Cancer Detection: A New Era for Pharmaceutical Companies In the ever-evolving landscape of healthcare, the integration of artificial intelligence (AI) into diagnostic p…
Amgen's Strategic Position in the Evolving Healthcare Landscape Amgen, a leading biotechnology company, stands at a critical juncture in the rapidly changing healthcare environment shaped by recent go…
Amgen and Ro Collaborate to Enhance Access to Obesity Treatments Amgen, a prominent player in the biopharmaceutical industry, partners with Ro, a direct-to-patient healthcare company, to address signi…
Amgen and Ro Join Forces to Enhance Access to Obesity Treatments Amgen collaborates with Ro, a direct-to-patient healthcare company, to research barriers to obesity treatment access, focusing on GLP-1…
Amgen Partners with Ro to Enhance Access to Obesity Treatment In a significant development for the healthcare landscape, Amgen collaborates with Ro, a direct-to-patient healthcare company, to tackle t…
Amgen Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics Amgen Inc. announces its strategic acquisition of Dark Blue Therapeutics, a biotechnology firm specializing in precision onc…
Amgen Expands Oncology Portfolio with Dark Blue Therapeutics Acquisition Amgen, a leader in biotechnology, solidifies its commitment to oncology by acquiring Dark Blue Therapeutics, a pioneering biote…
### Amgen's Strategic Acquisition of Dark Blue Therapeutics: A Leap Forward in Oncology Amgen Inc. announces its acquisition of Dark Blue Therapeutics, a pivotal move aimed at enhancing its oncology p…
Amgen Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics Amgen has made a significant move in its commitment to oncology by acquiring Dark Blue Therapeutics, a biotech firm based in…
Verastem Oncology Discontinues RAMP 203 Trial Amid Efficacy Concerns Verastem Oncology announces the discontinuation of its RAMP 203 trial, which aimed to explore the efficacy of a treatment targeting…
Novo Nordisk's Strategic Shift: The Launch of Wegovy-in-a-Pill Novo Nordisk is making significant waves in the weight loss industry with the recent approval of its oral medication, Wegovy, marking a p…
Novo Nordisk's Strategic Shift: The Rise of Wegovy in the Weight Loss Market In a significant turnaround for Novo Nordisk, the company finds itself reinvigorated with the U.S. approval of Wegovy, an o…
Roche CEO Raises Alarm on U.S. Drug Pricing Policies and Global Implications In recent statements, Thomas Schinecker, CEO of Roche Holding AG, articulates significant concerns regarding the impact of…
Transforming Drug Pricing: A New Era for American Healthcare In a landmark move, President Donald Trump announces a collaborative effort with nine major pharmaceutical companies aimed at reducing medi…
Amgen's Commitment to Affordable Healthcare Through Innovative Drug Pricing Models Amgen, the biotechnology giant based in Thousand Oaks, California, reinforces its dedication to affordable healthcare…
Amgen Reinforces Commitment to Affordable Healthcare through Innovative Pricing Strategies Amgen, a leading biotechnology company based in Thousand Oaks, California, is taking significant steps to enh…
Amgen's Uplinza: A New Era for Generalized Myasthenia Gravis Treatment In a pivotal development for patients suffering from generalized myasthenia gravis (gMG), the U.S. Food and Drug Administration (…